Machine-learning Optimization for Prostate Brachytherapy Planning
Condition: Prostatic Neoplasms Interventions: Other: Machine Learning Planning; Other: Radiation Therapist Planning Sponsor: Sunnybrook Health Sciences Centre Not yet recruiting - verified October 2016
Conclusions: In our exploratory study of stage III and IV NSCLC patients with CAO, addition of PDT demonstrated hazard of mortality comparable to radiation + chemotherapy group. However, addition of non-PDT ablation showed higher mortality compared to the radiation + chemotherapy group. Future studies should investigate the efficacy and effectiveness of multimodal therapy including radiation, chemo, immunotherapy and bronchoscopic interventions. PMID: 31737325 [PubMed]
To report the feasibility and safety of Diffusing Alpha-emitter Radiation Therapy (DaRT), which entails the interstitial implantation of a novel alpha-emitting brachytherapy source, for the treatment of locally advanced and recurrent squamous cancers (SCC) of the skin and head and neck.
Promoting prostate HDR in US would not be bad. scarbrtj said: In theory based on this chart could single fraction prostate HDR pay $23K global? If so look out for a prostate HDR renaissance in the US. CMS is, wittingly or unwittingly, massively incentivizing (and disincentivizing) certain treatment paradigms with this new model. For better or worse! Click to expand...
ConclusionBrachytherapy with planned GTR improved PFS in recurrent high-grade meningioma patients who exhausted prior external beam radiation treatment options. Future improvement of brachytherapy dose delivery methods and techniques may continue to prolong control rates and improve outcomes for this challenging group of patients.
The purpose of this study was to investigate the rate of compliance of air kerma strength (AKS) measurements of iodine-125 (I-125) seeds with international recommendations by departments in Australia and determine the potential impact of noncompliance.
As this year's Henschke Award recipient, I am extremely proud that the discipline of prostate brachytherapy has been studied carefully in a scientific manner with the procedure evolving from good to better to best. However, I am concerned regarding the long-term viability of brachytherapy. All successful organizations experience ups and downs and whether one is in the operating room, the board room, or on the playing field, it is clear that wins and losses and successes and failures are measured by the slimmest of margins.
AbstractEye Plaque brachytherapy pre-treatment quality assurance (QA) conducted clinically involves an activity verification of individual seeds via well chamber and does not include a physical measurement of dose-rate of the final assembly. A novel spectroscopic, dose-rate detection system, was evaluated for pre-treatment QA of eye plaque brachytherapy. The system includes a water phantom with sterility management. The system was calibrated using a known-activity I-125 seed, measured at 1 cm in water along the radial axis, compared to TG-43 U1 calculations and verified over a number of distances. A depth dose curve ...
Radio-recurrent prostate cancer is typically detected by a rising PSA and may reflect local or distant disease. PET radiotracers targeting PSMA such as 18F-DCFPyL have shown promise in restaging men with recurrent disease post-prostatectomy but are less well characterized in the setting of radio-recurrent disease.
Conclusion: LDR-EBRT may provide more effective PSA control at 5 years compared with HDR-EBRT. Direct comparison of these treatments through randomised trials are recommended to investigate this hypothesis further. PMID: 31701035 [PubMed]
AbstractProstate cancer is the most common cancer among men in the USA. Interestingly, recent studies suggest that patients with inflammatory bowel disease (IBD) are at increased risk of developing prostate cancer. Importantly, patients with IBD who develop prostate cancer require thoughtful care when using immunosuppressants to treat the IBD in the setting of malignancy. Further, consideration must be given to the proximity of the prostate to the gastrointestinal tract when treating with radiation where there is concern for the effects of inadvertent exposure of radiation to the diseased bowel. In general, management of i...